CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?
作者信息
Wolff Antonio C
机构信息
The Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD.
出版信息
J Clin Oncol. 2020 Dec 1;38(34):3977-3979. doi: 10.1200/JCO.20.02688. Epub 2020 Sep 20.
PMID:32954928
Abstract
摘要
相似文献
1
CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?早期乳腺癌中的CDK4/6抑制：新的标准？
J Clin Oncol. 2020 Dec 1;38(34):3977-3979. doi: 10.1200/JCO.20.02688. Epub 2020 Sep 20.
2
CDK4/6 inhibitors for HRHER2 early stage breast cancer - when to escalate treatment?用于激素受体阳性/人表皮生长因子受体2阴性早期乳腺癌的细胞周期蛋白依赖性激酶4/6抑制剂——何时加强治疗？
Nat Rev Clin Oncol. 2021 Feb;18(2):67-68. doi: 10.1038/s41571-020-00453-1.
3
Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib.细胞周期蛋白依赖性激酶 4/6 抑制剂在乳腺癌中的应用：帕博西尼、瑞博西尼和阿贝西利。
Breast Cancer Res Treat. 2017 Nov;166(1):41-54. doi: 10.1007/s10549-017-4385-3. Epub 2017 Jul 24.
4
Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.乳腺癌治疗性 CDK4/6 抑制的作用机制。
Semin Oncol. 2017 Dec;44(6):385-394. doi: 10.1053/j.seminoncol.2018.01.006.
5
Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.乳腺癌中环磷酰胺依赖性激酶 4/6 抑制剂相关毒性和药物相互作用的临床处理：实用注意事项和建议。
Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13.
6
CDK4/6 Inhibition as a therapeutic strategy in breast cancer: palbociclib, ribociclib, and abemaciclib.CDK4/6 抑制作为乳腺癌的治疗策略：帕博西利、瑞博西利和阿贝西利。
Semin Oncol. 2017 Dec;44(6):395-403. doi: 10.1053/j.seminoncol.2018.03.006. Epub 2018 Mar 26.
7
CDK4/6 blockade in breast cancer: current experience and future perspectives.乳腺癌中的CDK4/6阻断：当前经验与未来展望
Expert Opin Investig Drugs. 2017 Dec;26(12):1357-1372. doi: 10.1080/13543784.2017.1389896. Epub 2017 Oct 23.
8
Cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive early breast cancer: preliminary results and ongoing studies.细胞周期蛋白依赖性激酶 4/6 抑制剂在激素受体阳性早期乳腺癌中的应用：初步结果和正在进行的研究。
Breast Cancer. 2018 Sep;25(5):506-516. doi: 10.1007/s12282-018-0864-6. Epub 2018 Apr 26.
9
CDK4/6 inhibitors prolong OS.细胞周期蛋白依赖性激酶4/6抑制剂可延长总生存期。
Nat Rev Clin Oncol. 2019 Dec;16(12):722. doi: 10.1038/s41571-019-0288-z.
10
Abemaciclib (Verzenio)--a third CDK 4/6 inhibitor for breast cancer.阿贝西利（唯择）——第三种用于乳腺癌的细胞周期蛋白依赖性激酶4/6抑制剂。
Med Lett Drugs Ther. 2017 Nov 6;59(1533):185-186.
引用本文的文献
1
Feasibility of Adjuvant Treatment with Abemaciclib-Real-World Data from a Large German Breast Center.阿贝西利辅助治疗的可行性——来自德国一家大型乳腺中心的真实世界数据
J Pers Med. 2022 Mar 2;12(3):382. doi: 10.3390/jpm12030382.
2
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER/HER2 Breast Cancer.ER/HER2 阳性乳腺癌患者中帕博西尼联合来曲唑的反应和耐药生物标志物。
Clin Cancer Res. 2022 Jan 1;28(1):163-174. doi: 10.1158/1078-0432.CCR-21-1628. Epub 2021 Oct 13.
Zotero 插件